Friday, 29 March 2024


Japan picks Daiichi Sankyo for COVID-19 vaccine supply

17 August 2020 | News

Daiichi Sankyo will develop a supply system for DS-5670

Image credit- shutterstock.com

Image credit- shutterstock.com

Daiichi Sankyo Company has announced that it was selected by the Ministry of Health, Labour and Welfare of Japan to be a provider for the Japanese Government’s “Emergent Initiative to Build Production Capacity for COVID-19 Vaccines (First Round)” with respect to Daiichi Sankyo’s genetic (mRNA) vaccine (hereinafter, DS-5670) for the novel corona virus infection (hereinafter, COVID-19).

DS-5670 is a gene (mRNA) vaccine for COVID-19 using a novel nucleic acid delivery technology discovered by Daiichi Sankyo, and as one of the company’s top-priority projects, it is being prepared to enter clinical studies around March 2021.

Daiichi Sankyo will develop a supply system for DS-5670 at the plant of its subsidiary company, Daiichi Sankyo Biotech Co., Ltd., located in Kitamoto City, Saitama Prefecture, and aims to build a platform for production technology in Japan that can respond not only to COVID-19 but also to the need for future emerging and re-emerging infectious disease vaccines.

In addition to the aforementioned supply of DS-5670, Daiichi Sankyo will proactively continue efforts to establish prevention and treatment methods for COVID-19, which has become an urgent social need.

The Emergent initiative aims to swiftly develop an actual (large-scale) production system for biologics, including vaccines, in order to ensure that the vaccines necessary for the prevention of the spread and severity of unexpected epidemics, including COVID-19, are produced as soon as possible, and that their supply is secured for the Japanese people.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account